title: Tuberculous lymphadenopathy: a multicentre operational study of 6-month thrice weekly directly observed treatment.
abstract: METHODS
  Eight operational locations for the Revised National Tuberculosis Control Programme in six Indian states.
  
  
  OBJECTIVE
  To assess the 6-month efficacy of an intermittent thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy and the need  for prolongation of treatment to 9 months for non-resolution of lymphadenopathy.
  
  
  METHODS
  Patients aged >5 years with tuberculous lymphadenopathy were included in the study. Patients were evaluated for resolution at repeat visits following treatment. Those with poor resolution at 6 months  were randomised to extended treatment up to 9 months or observation without additional treatment.
  
  
  RESULTS
  Resolution of lymphadenopathy was observed at the end of 6 months in 517/551 (93.8%) patients. There was a significant difference in response among patients with and those without  the presence of systemic symptoms. There was no association between treatment response and number, size, site, consistency and matting of lymphadenopathy. No differences in response were seen in the remaining 34 patients with or without extended treatment.
  
  
  CONCLUSIONS
  The operational efficacy  of 6-month thrice-weekly DOT for peripheral tubercular lymphadenopathy was satisfactory. There was no evidence of additional benefits of prolonging treatment to 9 months.
authors: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India. dr.skjindal@gmail.com
authors: S K
authors: SK
authors: Jindal
authors: A N
authors: AN
authors: Aggarwal
authors: D
authors: D
authors: Gupta
authors: Z
authors: Z
authors: Ahmed
authors: K B
authors: KB
authors: Gupta
authors: A K
authors: AK
authors: Janmeja
authors: S
authors: S
authors: Kashyap
authors: M
authors: M
authors: Singh
authors: A
authors: A
authors: Mohan
authors: J
authors: J
authors: Whig
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D023801:Directly Observed Therapy / Q000379:methods*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014388:Tuberculosis, Lymph Node / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin